These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24525259)

  • 1. Human pharmaceutical products in the environment - the "problem" in perspective.
    Taylor D; Senac T
    Chemosphere; 2014 Nov; 115():95-9. PubMed ID: 24525259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrated approach for prioritizing pharmaceuticals found in the environment for risk assessment, monitoring and advanced research.
    Caldwell DJ; Mastrocco F; Margiotta-Casaluci L; Brooks BW
    Chemosphere; 2014 Nov; 115():4-12. PubMed ID: 24636702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The challenge: do pharmaceuticals present a risk to the environment, and what needs to be done to answer the question?
    Sumpter JP
    Environ Toxicol Chem; 2014 Sep; 33(9):1915. PubMed ID: 25138028
    [No Abstract]   [Full Text] [Related]  

  • 4. Environmental risk analysis and prioritization of pharmaceuticals in a developing world context.
    Mansour F; Al-Hindi M; Saad W; Salam D
    Sci Total Environ; 2016 Jul; 557-558():31-43. PubMed ID: 26994791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are pharmaceuticals potent environmental pollutants? Part I: environmental risk assessments of selected active pharmaceutical ingredients.
    Carlsson C; Johansson AK; Alvan G; Bergman K; Kühler T
    Sci Total Environ; 2006 Jul; 364(1-3):67-87. PubMed ID: 16257037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemicals of emerging concern in the Great Lakes Basin: an analysis of environmental exposures.
    Klecka G; Persoon C; Currie R
    Rev Environ Contam Toxicol; 2010; 207():1-93. PubMed ID: 20652664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceuticals in the environment--a human risk?
    Christensen FM
    Regul Toxicol Pharmacol; 1998 Dec; 28(3):212-21. PubMed ID: 10049792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PBT assessment and prioritization of contaminants of emerging concern: Pharmaceuticals.
    Sangion A; Gramatica P
    Environ Res; 2016 May; 147():297-306. PubMed ID: 26921826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are pharmaceuticals potent environmental pollutants? Part II: environmental risk assessments of selected pharmaceutical excipients.
    Carlsson C; Johansson AK; Alvan G; Bergman K; Kühler T
    Sci Total Environ; 2006 Jul; 364(1-3):88-95. PubMed ID: 16260028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International scientists' priorities for research on pharmaceutical and personal care products in the environment.
    Rudd MA; Ankley GT; Boxall AB; Brooks BW
    Integr Environ Assess Manag; 2014 Oct; 10(4):576-87. PubMed ID: 24954797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Matthew Effect and widely prescribed pharmaceuticals lacking environmental monitoring: case study of an exposure-assessment vulnerability.
    Daughton CG
    Sci Total Environ; 2014 Jan; 466-467():315-25. PubMed ID: 23911922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving environmental risk assessment of human pharmaceuticals.
    Ågerstrand M; Berg C; Björlenius B; Breitholtz M; Brunström B; Fick J; Gunnarsson L; Larsson DG; Sumpter JP; Tysklind M; Rudén C
    Environ Sci Technol; 2015 May; 49(9):5336-45. PubMed ID: 25844810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experiences with the OECD 308 transformation test: a human pharmaceutical perspective.
    Ericson JF; Smith RM; Roberts G; Hannah B; Hoeger B; Ryan J
    Integr Environ Assess Manag; 2014 Jan; 10(1):114-24. PubMed ID: 23794155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical metabolites in the environment: analytical challenges and ecological risks.
    Celiz MD; Tso J; Aga DS
    Environ Toxicol Chem; 2009 Dec; 28(12):2473-84. PubMed ID: 19663539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factory-discharged pharmaceuticals could be a relevant source of aquatic environment contamination: review of evidence and need for knowledge.
    Cardoso O; Porcher JM; Sanchez W
    Chemosphere; 2014 Nov; 115():20-30. PubMed ID: 24602347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioaccumulation and biomagnification potential of pharmaceuticals with a focus to the aquatic environment.
    Zenker A; Cicero MR; Prestinaci F; Bottoni P; Carere M
    J Environ Manage; 2014 Jan; 133():378-87. PubMed ID: 24419205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary risk assessment database and risk ranking of pharmaceuticals in the environment.
    Cooper ER; Siewicki TC; Phillips K
    Sci Total Environ; 2008 Jul; 398(1-3):26-33. PubMed ID: 18440598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging pollutants, and communicating the science of environmental chemistry and mass spectrometry: pharmaceuticals in the environment.
    Daughton CG
    J Am Soc Mass Spectrom; 2001 Oct; 12(10):1067-76. PubMed ID: 11605967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human pharmaceuticals in surface waters. Implementation of a prioritization methodology and application to the French situation.
    Besse JP; Garric J
    Toxicol Lett; 2008 Jan; 176(2):104-23. PubMed ID: 18077113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceuticals in the environment--Global occurrences and perspectives.
    aus der Beek T; Weber FA; Bergmann A; Hickmann S; Ebert I; Hein A; Küster A
    Environ Toxicol Chem; 2016 Apr; 35(4):823-35. PubMed ID: 26666847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.